Sheng-Li Xue, MD
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Venetoclax Combined With Azactidine in the Treatment of ALAL (NCT05901974) | Sheng-Li Xue, MD | 2023-07-01 |
| Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL (NCT05940961) | Sheng-Li Xue, MD | 2022-08-01 |
Track Sheng-Li Xue, MD automatically
Every clearance here is in the API, with alerts when new ones post.